论文部分内容阅读
目的 :探讨一种既能改善食道癌性狭窄所致的吞咽困难 ,又能抑制肿瘤生长的治疗手段。方法 :在 1 996～ 1 999年期间 ,采用舒林酸 (sulindac)、支架、放疗 2 6例患者 ,与同期间硒宝康、支架、放疗 2 2例患者进行对照观察 ,比较两组的吞咽困难积分改善情况和 3年存活率。结果 :舒林酸组与硒宝康组吞咽困难积分无显著差异 (P >0 .0 5) ,3年生存率分别为 46 .5 %和 2 2 .7%。P <0 .0 5有显著差异。结论 :舒林酸、支架、放疗对晚期食管癌治疗具有较多好疗效 ,既改善了吞咽困难 ,又控制肿瘤细胞生长 ,达到标本兼治的作用
Objective: To explore a kind of treatment that can both improve dysphagia and inhibit tumor growth caused by cancerous esophageal stenosis. Methods: From 1996 to 1999, 26 patients were treated with sulindac, scaffold and radiotherapy, compared with 22 patients with sebacol, stent and radiotherapy during the same period. The swallowing was compared between the two groups Difficult points to improve the situation and 3-year survival rate. Results: There were no significant differences in dysphagia scores between sulindac and selenium (P> 0.05). The 3-year survival rates were 46.5% and 22.7%, respectively. P <0 0 5 significant difference. Conclusion: Sulindac, stents and radiotherapy have more good curative effect on the treatment of advanced esophageal cancer, which not only improves the dysphagia but also controls the growth of tumor cells,